Thursday May 25th 2017

Archive for April, 2017

MS Society of Canada Urges Members of Parliament to Act to Improve #LifeWithMS

MS Society of Canada Urges Members of Parliament to Act to Improve #LifeWithMS

Multiple Sclerosis Society of Canada and members of MS community to launch MS Awareness Month in Ottawa with focus on getting government to take action to improve Life With MS (Source: Disabled World) [Read More]

CME Outfitters Demonstrates Successful Integration of the Patient…

CME Outfitters Demonstrates Successful Integration of the Patient…

CMEO webcast activity on multiple sclerosis proves successful in incorporating the patient voice directly into educational content(PRWeb April 29, 2017)Read the full story at http://www.prweb.com/releases/2017/05/prweb14292245.htm (Source: PRWeb: Medical [Read More]

Nose2Brain project aims to develop better therapy for multiple sclerosis

Nose2Brain project aims to develop better therapy for multiple sclerosis

Medically active substances are normally distributed via the blood - either directly by injection into the bloodstream or indirectly, for example through the digestive tract after oral administration. [Read More]

 Page 1 of 24  1  2  3  4  5 » ...  Last » 

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]